Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 176

1.
2.

HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair.

Koll TT, Feis SS, Wright MH, Teniola MM, Richardson MM, Robles AI, Bradsher J, Capala J, Varticovski L.

Mol Cancer Ther. 2008 Jul;7(7):1985-92. doi: 10.1158/1535-7163.MCT-07-2104.

3.

Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cells.

Rao R, Lee P, Fiskus W, Yang Y, Joshi R, Wang Y, Buckley K, Balusu R, Chen J, Koul S, Joshi A, Upadhyay S, Tao J, Sotomayor E, Bhalla KN.

Cancer Biol Ther. 2009 Jul;8(13):1273-80.

4.

Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.

Schwock J, Pham NA, Cao MP, Hedley DW.

Cancer Chemother Pharmacol. 2008 Apr;61(4):669-81. Epub 2007 Jun 20.

PMID:
17579866
5.

The apoptotic effect and associated signalling of HSP90 inhibitor 17-DMAG in hepatocellular carcinoma cells.

Leng AM, Liu T, Yang J, Cui JF, Li XH, Zhu YN, Xiong T, Zhang G, Chen Y.

Cell Biol Int. 2012 Oct 1;36(10):893-9. doi: 10.1042/CBI20110473.

PMID:
22694478
6.

Inhibition of Hsp90 via 17-DMAG induces apoptosis in a p53-dependent manner to prevent medulloblastoma.

Ayrault O, Godeny MD, Dillon C, Zindy F, Fitzgerald P, Roussel MF, Beere HM.

Proc Natl Acad Sci U S A. 2009 Oct 6;106(40):17037-42. doi: 10.1073/pnas.0902880106. Epub 2009 Sep 23.

7.

The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor.

Kobayashi N, Toyooka S, Soh J, Yamamoto H, Dote H, Kawasaki K, Otani H, Kubo T, Jida M, Ueno T, Ando M, Ogino A, Kiura K, Miyoshi S.

Lung Cancer. 2012 Feb;75(2):161-6. doi: 10.1016/j.lungcan.2011.04.022. Epub 2011 Jul 20.

PMID:
21767894
8.

17-DMAG induces heat shock protein 90 functional impairment in human bladder cancer cells: knocking down the hallmark traits of malignancy.

Karkoulis PK, Stravopodis DJ, Voutsinas GE.

Tumour Biol. 2016 May;37(5):6861-73. doi: 10.1007/s13277-015-4544-2. Epub 2015 Dec 11.

PMID:
26662567
9.

The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression.

Georgakis GV, Li Y, Rassidakis GZ, Medeiros LJ, Younes A.

Exp Hematol. 2006 Dec;34(12):1670-9.

PMID:
17157164
10.

17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.

Babchia N, Calipel A, Mouriaux F, Faussat AM, Mascarelli F.

Invest Ophthalmol Vis Sci. 2008 Jun;49(6):2348-56. doi: 10.1167/iovs.07-1305. Epub 2008 Feb 15.

PMID:
18281615
11.

Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin.

Bull EE, Dote H, Brady KJ, Burgan WE, Carter DJ, Cerra MA, Oswald KA, Hollingshead MG, Camphausen K, Tofilon PJ.

Clin Cancer Res. 2004 Dec 1;10(23):8077-84.

13.

Combined effects of 17-DMAG and TNF on cells through a mechanism related to the NF-kappaB pathway.

Qu Z, Dong H, Xu X, Feng W, Yi X.

Diagn Pathol. 2013 May 1;8:70. doi: 10.1186/1746-1596-8-70.

14.

Heat shock protein 90 inhibitors: new mode of therapy to overcome endocrine resistance.

Wong C, Chen S.

Cancer Res. 2009 Nov 15;69(22):8670-7. doi: 10.1158/0008-5472.CAN-09-1259. Epub 2009 Oct 27.

15.

[Effects of 17-DMAG on non-small cell lung cancer cell lines A549 and H1975
 being resistant to EGFR-TKI].

Zhao L, Cao F.

Zhongguo Fei Ai Za Zhi. 2014 Nov;17(11):778-82. doi: 10.3779/j.issn.1009-3419.2014.11.02. Chinese.

16.

P53-dependent radiosensitizing effects of Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin on human oral squamous cell carcinoma cell lines.

Shintani S, Zhang T, Aslam A, Sebastian K, Yoshimura T, Hamakawa H.

Int J Oncol. 2006 Nov;29(5):1111-7.

PMID:
17016641
18.

90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1.

Tse AN, Sheikh TN, Alan H, Chou TC, Schwartz GK.

Mol Pharmacol. 2009 Jan;75(1):124-33. doi: 10.1124/mol.108.050807. Epub 2008 Sep 26.

19.

Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator.

Kaur G, Belotti D, Burger AM, Fisher-Nielson K, Borsotti P, Riccardi E, Thillainathan J, Hollingshead M, Sausville EA, Giavazzi R.

Clin Cancer Res. 2004 Jul 15;10(14):4813-21.

20.

Targeted polytherapy in small cell sarcoma and its association with doxorubicin.

Dumont SN, Yang D, Dumont AG, Reynoso D, Blay JY, Trent JC.

Mol Oncol. 2014 Dec;8(8):1458-68. doi: 10.1016/j.molonc.2014.05.016. Epub 2014 Jun 10.

Supplemental Content

Support Center